Manchester on the map after Government windfall
Manchester is today celebrating
success after securing £12.5million of Government funding for
The Wellcome Trust Clinical Research
Facility and The Wellcome Trust Children's Clinical Research
Facility (WTCRFs), at Central Manchester University Hospitals NHS
Foundation Trust and two leading hospital trusts, working closely
with The University of Manchester, have been awarded the money to
carry out research into many of the major diseases and
illnesses that affect the population of Greater Manchester and the
wider North West.
The three Clinical Research Facilities that will receive funding
- Central Manchester University Hospitals NHS Foundation
Trust who will use the £5.5 million funding to support
studies for people with diseases such as arthritis, psoriasis,
depression, addiction, and diabetes.
- The Christie NHS Foundation Trust who will use
the £4.5million funding to support early-stage trials of treatments
for people with cancer.
- University Hospital of South Manchester NHS Foundation
Trust who will use the £2.5million funding to support
early-stage trials of treatments for people with lung diseases such
as asthma, fungal infection, chronic obstructive pulmonary disease,
and also food allergies.
The WTCRFs at Central Manchester University
Hospitals NHS Foundation Trust will expand world class Experimental
Medicine in areas of high priority and unmet need including
arthritis, mental health, cardiovascular disease, diabetes,
dermatology, paediatrics and genetic medicine. The WTCRFs also
support the brand new £6 million NIHR Manchester Musculoskeletal
Biomedical Research Unit and Translational Research Partnership in
Joint and Related Inflammatory Disease in their goal of 'Treating
Arthritis: Right First Time'.
Mike Deegan, Chief Executive of Central Manchester University
Hospitals NHS Foundation Trust "Congratulations to the WTCRFs team
on being awarded this funding to continue their excellent work in
experimental medicine. This reinforces Manchester's strong
credentials in experimental medicine and will play a key role in
constant improvements to treatment for our patients."
Professor Ian Bruce, Medical Director of the WTCRFs said "This
funding from NIHR confirms the quality of work already being done
in Manchester and will help us develop our vision of supporting
innovation in an environment where new discoveries can be
translated into human diseases to improve the health and wealth of
Researchers believe the success of these bids reflects the scale
of expertise in conducting clinical trials in NHS organisations in
Manchester and the University of Manchester which collectively form
MAHSC (Manchester Academic Health Science Centre).
Professor Ian Jacobs is Director of MAHSC and Vice President of
the University of Manchester. He believes this is a Red Letter Day
for Manchester and further enhances the reputation of the city as a
leading international centre for healthcare and health science.
He explains: "An extraordinary level of collaborative joint
working has been achieved which makes it possible to conduct trials
of the highest quality, on a large scale in a broad range of health
areas including cancer, respiratory, neurological, cardiovascular,
musculoskeletal and inflammatory disorders. This funding will lead
to new healthcare innovations which will be rapidly applied for the
benefit of our population through the MAHSC partnership."
Professor Dame Nancy Rothwell, President and Vice-Chancellor of
The University of Manchester, said: "These important awards
build on the great strengths across the University and its partner
NHS Trusts and span our research from basic discovery through to
NHS Trusts and Foundation Trusts with clinical research
facilities submitted bids for the funding, which were judged by a
panel of UK experts in both medical research and in running
clinical research facilities. Winning bids were selected on the
basis of the quality and volume of world-class medical research
they support as well as other criteria including the strength of
their partnerships with universities and industry
Secretary of State for Health, Andrew Lansley
says: "Both public and patients think it's important that the NHS
should support research into new treatments, and we agree. That's
why we're investing over £100m in research facilities, nurses and
technicians to help make the NHS a world-class place to do
"These researchers will push forward the boundaries of what is
possible. These are the people and the labs where the very best new
treatments will be developed for a huge range of conditions - from
cancer to diabetes and heart disease. NHS patients are the ones who
will see the benefit of their work."
Professor Dame Sally Davies, Chief Medical Officer and
Chief Scientific Advisor at the Department of Health says:
"These are very exciting times for clinical research in the UK, and
this funding is a reflection of the commitment we have to
supporting world-class experimental medicine.
"The Clinical Research Facilities will play a key role in
supporting advances in treatments for a wide variety of diseases
and supporting collaboration with industry. Thousands of people
will benefit right across the country."
The two other bids explained
The Christie NHS Foundation Trust - The
Christie has been awarded £4.5 million to support its Phase I/II
Cancer Trials Unit in recognition of the outstanding early phase
research work already carried out.
Andrew Wardley, director of the Phase I/II Cancer Trials Unit at
The Christie, said: "This funding is vital for our research
infrastructure over the next four years. It's not only
important for developing trials of new drugs in cancer, but will
also help improve our ability to develop individualised treatment
plans - which will in turn significantly help us make further
advances in the treatment of cancer. We're also
delighted to see that other research facilities in Manchester have
been awarded essential funding."
The Christie Phase I/II Cancer Trials Unit opened in late 2010
conducts early phase research and is home to many firsts into human
studies. As well as these early phase trials, the unit
conducts later phase research across a range of different
University Hospital South Manchester- The
Respiratory and Allergy Clinical Research Facility at UHSM, based
at Wythenshawe Hospital is ideally placed to deliver experimental
medicine in important diseases of considerable unmet need including
food allergy, chronic cough, fungal lung disease and COPD. Our
existing CRF has built on substantial NIHR investment to develop
innovative tools and techniques (e.g. food challenge materials,
cough monitors) for objective measurement of outcomes. The close
interaction with The University of Manchester basic laboratory
science in a hospital setting has facilitated this capability, but
also ensured that new ideas are `pulled' from patients to inform
advances in basic science.
Professor Ashley Woodcock at UHSM explains: "Our track record in
early phase respiratory trials has demonstrated that our science
innovation is rapidly translated into patient benefit. We have a
history of powerful, mutually beneficial collaborative working with
industry and participate in the NIHR Translational Research
Partnership in Inflammatory Respiratory Diseases.
"Our strategy is to capitalise upon our areas of expertise to
further develop clinical innovations for patient benefit
(preventative methods, diagnostics), and to optimise efficacy and
minimise toxicity of current and new therapies."
MAHSC is a partnership between The University of Manchester,
Central Manchester University Hospitals NHS Foundation Trust,
Manchester Mental Health and Social Care Trust, NHS Salford
(Salford Primary Care Trust), Salford Royal NHS Foundation Trust,
The Christie NHS Foundation Trust, University Hospital of South
Manchester NHS Foundation Trust.
For further information please contact:
Web Communications Officer
NIHR Manchester Biomedical Research Centre
0161 701 0260 / 0782 514 2219